文献速递临床试验与 GCP基础与转化研究

124I-Evuzamitide PET/CT 诊断心脏淀粉样变性:REVEAL 非随机临床试验

124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial.
PubMed 文献 · JAMA · 2026-08-30

REVEAL 研究为前瞻性、多中心、单组研究,纳入 195 例疑似心脏淀粉样变性成人,最终 170 例纳入分析,评估 124I-evuzamitide PET/CT 的诊断效能。结果显示总体灵敏度 94%(95%CI 85%-98%),特异度 86%(95%CI 77%-92%),阳性预测值 85%(95%CI 75%-92%),阴性预测值 94%(95%CI 87%-98%),支持其作为疑似患者的诊断检查。

要点

  • 124I-evuzamitide PET/CT 诊断心脏淀粉样变性灵敏度 94%、特异度 86%。
  • 阳性预测值 85%,阴性预测值 94%,阴性结果有助于排除诊断。
  • 该检查可无创直接显像心脏淀粉样沉积,不限于转甲状腺素蛋白型。

核心结论

  • 124I-evuzamitide PET/CT 对诊断心脏淀粉样变性具有高灵敏度和特异度,安全性可接受,支持其作为疑似患者的诊断检查。

研究设计与样本

  • 前瞻性、多中心、单组研究,在美国 18 个中心开展,研究时间为 2025 年 1 月 14 日至 2026 年 3 月 12 日,含 60 天随访期。
  • 共入组 195 例疑似心脏淀粉样变性成人,排除已确诊心脏或系统性淀粉样变性者,最终 170 例纳入分析。
  • 3 名有心脏 PET/CT 经验的医师在盲法下独立判读视觉心肌 124I-evuzamitide 摄取,3 名淀粉样变性专家在盲法下依据标准诊疗诊断算法独立裁定诊断。
  • PET/CT 于静脉注射 1 mCi 124I-evuzamitide 后 3 至 5 小时采集,注射前至少 30 分钟起口服碘化钾 130 mg 持续 3 天。

主要发现

  • 总体灵敏度 94%(95%CI 85%-98%,P < .001),特异度 86%(95%CI 77%-92%,P < .001)。
  • 阳性预测值 85%(95%CI 75%-92%),阴性预测值 94%(95%CI 87%-98%)。
  • 纳入分析 170 例,中位年龄 72 岁(IQR 64-79),男性 75.3%,黑人 19.2%,白人 79.0%。
  • 中位 N 末端脑钠肽前体 471 pg/mL,61.7% 有纽约心功能协会 II 或 III 级心衰症状。

关键数值与推荐

  • 诊断心脏淀粉样变性的灵敏度为 94%(95%CI 85%-98%,P < .001),特异度为 86%(95%CI 77%-92%,P < .001)。
  • 阳性预测值为 85%(95%CI 75%-92%),阴性预测值为 94%(95%CI 87%-98%)。

临床怎么用

  • 对疑似心脏淀粉样变性患者,可考虑行 124I-evuzamitide PET/CT 进行无创诊断评估。
  • 检查前需口服碘化钾 130 mg 持续 3 天以保护甲状腺,并于注射后 3 至 5 小时采集图像。
  • 判读时以心肌视觉摄取为阳性标准,阴性结果对排除诊断有较高价值(阴性预测值 94%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Diagnosing cardiac amyloidosis remains challenging because current imaging approaches are limited to transthyretin amyloidosis. A noninvasive test capable of directly imaging cardiac amyloidosis from various amyloid types and in multiple organs could address an important unmet diagnostic need. OBJECTIVE: To evaluate the sensitivity and specificity of 124I-evuzamitide positron emission tomography (PET)/computed tomography (CT) for diagnosing cardiac amyloidosis. DESIGN, SETTING, AND PARTICIPANTS: Prospective, multicenter (18 US centers), single-group study evaluating the efficacy of 124I-evuzamitide to diagnose cardiac amyloidosis. This study was conducted from January 14, 2025, to March 12, 2026, including a 60-day follow-up period. Three physicians with cardiac PET/CT experience independently reviewed PET/CT images for visual cardiac 124I-evuzamitide uptake while blinded to clinical data. Three expert clinical amyloidosis physicians, blinded to PET/CT data, independently adjudicated the diagnosis based on the standard-of-care diagnostic algorithm. A total of 195 adults suspected of having cardiac amyloidosis were enrolled when they presented for diagnostic evaluation at participating institutions, excluding patients with an established diagnosis of cardiac or systemic amyloidosis. INTERVENTIONS: PET/CT scans were obtained 3 to 5 hours after intravenous administration of 1 mCi of 124I-evuzamitide. Potassium iodide (130 mg) was given orally for 3 days starting at least 30 minutes prior to 124I-evuzamitide injection. MAIN OUTCOMES AND MEASURES: Coprimary end points of this study were to assess the sensitivity and specificity of 124I-evuzamitide for the diagnosis of cardiac amyloidosis. RESULTS: Overall, 170 patients were included (median [IQR] age, 72 [64-79] years; 75.3% male, 19.2% Black, 79.0% White). Median N-terminal pro-brain natriuretic peptide was 471 pg/mL and 61.7% had New York Heart Association class II or III heart failure symptoms. The overall sensitivity was 94% (95% CI, 85%-98%; P < .001); specificity, 86% (95% CI, 77%-92%; P < .001); positive predictive value, 85% (95% CI, 75%-92%); and negative predictive value, 94% (95% CI, 87%-98%). CONCLUSIONS AND RELEVANCE: 124I-evuzamitide PET/CT is highly sensitive and specific for diagnosing cardiac amyloidosis with an acceptable safety profile. These results support 124I-evuzamitide PET/CT as a diagnostic test to evaluate patients with suspected cardiac amyloidosis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06788535.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Dorbala S, Maurer MS, Cuddy SAM, et al. 124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial. JAMA. 2026. PMID: 42669054. doi:10.1001/jama.2026.17361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。